Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is
transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments …

The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document:
Staging and multidisciplinary management of patients with early-stage non–small cell lung …

Abstract Treatment with 3 years of adjuvant osimertinib is considered a new standard in
patients with completely resected stage I to IIIA NSCLC harboring a common sensitizing …

Importance Surgical resection remains the preferred treatment for functionally fit patients
diagnosed with early-stage non–small cell lung cancer (NSCLC). Process-based …

Clinical investigation of immune checkpoint inhibitors (ICIs) has expanded from indications
in metastatic non–small cell lung cancer (NSCLC) to add to the treatment of early-stage or …

Anatomic surgical resection followed by cisplatin-based platinum-doublet adjuvant
chemotherapy has been a long-standing standard of care for patients with early-stage …

Introduction Recent trials have reported promising results with the addition of
immunotherapy to chemotherapy for patients with locally advanced NSCLC, but in practice …

Background Non-small cell lung cancer (NSCLC) accounts for 85% of all newly diagnosed
lung cancer cases. Among patients with NSCLC, about 20% are diagnosed with stage I and …